Literature DB >> 7726614

A survey of recommendations given to patients going home after bone marrow transplant.

L Brandt1, V Broadbent.   

Abstract

A postal questionnaire was sent to 11 UK Children's Cancer Study Group bone marrow transplant centres asking them for details of their instructions to patients on discharge after either allogeneic or auto transplant; nine centres responded. There was no recommendation on which they all agreed. Though all centres gave prophylactic septrin, the times of starting and stopping treatment varied considerably. Three centres recommended lifelong penicillin after total body irradiation, one treated for two years and five gave no such prophylaxis. Four of nine centres gave routine acyclovir for herpes simplex prophylaxis. Most centres suggested prophylaxis against varicella after contact exposure for one year. However, three gave zoster immune globulin alone, one gave this together with acyclovir, and five gave acyclovir alone. No two centres recommended the same dose of acyclovir. Vaccinations were allowed from 6-18 months after transplant. One centre required documentation of recovery of immune function first. Four centres recommended a child stay off school for six months; others had 'common sense' approaches. Only one centre did not allow family holidays for the first six months but many imposed restrictions on these holidays. Dietary restrictions varied greatly between centres. It is concluded that there is a need for unified and scientifically justified guidelines after transplant for paediatric bone marrow transplant patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7726614      PMCID: PMC1030091          DOI: 10.1136/adc.71.6.529

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  9 in total

1.  Varicella in children with cancer: impact of antiviral therapy and prophylaxis.

Authors:  S Feldman; L Lott
Journal:  Pediatrics       Date:  1987-10       Impact factor: 7.124

Review 2.  The utility of protected-environment regimens for the compromised host: a critical assessment.

Authors:  P A Pizzo; A S Levine
Journal:  Prog Hematol       Date:  1977

Review 3.  Infection control and bone marrow transplantation.

Authors:  B R Mooney; S A Reeves; E Larson
Journal:  Am J Infect Control       Date:  1993-06       Impact factor: 2.918

4.  Microbiological evaluation of food items. For patients undergoing gastrointestinal decontamination and protected isolation.

Authors:  P A Pizzo; D S Purvis; C Waters
Journal:  J Am Diet Assoc       Date:  1982-09

5.  Prevention of herpes zoster in patients by long-term oral acyclovir after allogeneic bone marrow transplantation.

Authors:  T J Perren; R L Powles; D Easton; K Stolle; P J Selby
Journal:  Am J Med       Date:  1988-08-29       Impact factor: 4.965

6.  Adenovirus infections in patients undergoing bone-marrow transplantation.

Authors:  A F Shields; R C Hackman; K H Fife; L Corey; J D Meyers
Journal:  N Engl J Med       Date:  1985-02-28       Impact factor: 91.245

Review 7.  Viral infections associated with bone marrow transplantation.

Authors:  J A Zaia
Journal:  Hematol Oncol Clin North Am       Date:  1990-06       Impact factor: 3.722

8.  Decline of serum antibody in splenectomized children after vaccination with pneumococcal capsular polysaccharides.

Authors:  G S Giebink; C T Le; G Schiffman
Journal:  J Pediatr       Date:  1984-10       Impact factor: 4.406

9.  Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis.

Authors:  W T Hughes; G K Rivera; M J Schell; D Thornton; L Lott
Journal:  N Engl J Med       Date:  1987-06-25       Impact factor: 91.245

  9 in total
  1 in total

1.  Impact of SARS-CoV-2 pandemic on rehabilitation of patients after high-dose chemotherapy with allogeneic hematopoietic stem cell transplantation: results of a monocentric, retrospective analysis.

Authors:  Thomas Kiefer; Christian Lüders; Heinz Völler; Georg Daeschlein
Journal:  J Cancer Res Clin Oncol       Date:  2022-10-14       Impact factor: 4.322

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.